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Objective: To study the inﬂuence of cisplatin implants on transplantation tumor growth
and the expression of tissue kallikrein-7 (KLK7) and E-cadherin (E-cad) in tumor-bearing
mice with gastric cancer.
Methods: BALB/c nude mice were collected as experimental animal and were randomly
divided into model control group (Group A), tail intravenous injection of cisplatin group
(Group B), intratumor injection of cisplatin group (Group C) and cisplatin implants
treatment group (Group D). After the drugs intervening, the weight and volume of
transplantation tumors were measured on Day 20, Day 30 and Day 40 and serum and
KLK7 and E-cad contents in transplanted tumor tissue were examined.
Results: On Day 20, Day 30 and Day 40 after treatment, the weight and volume of
transplantation tumors of tumor-bearing mice in four groups were different (Group
A > Group B > Group C > Group D). The contents of KLK-7 and E-cad in tumor tissue
and serum of tumor-bearing mice in four groups were different (Group A > Group
B > Group C > Group D in KLK-7) and (Group A < Group B < Group C < Group D in
E-cad). The weight and volume, and KLK7 and E-cad contents of transplantation tumors
in four groups were signiﬁcant difference (P < 0.05).
Conclusion: Cisplatin implants can inhibit the growth of transplanted tumor tissue and
down-regulated KLK7 expression and up-regulated E-cad expression of tumor-bearing
mice with gastric cancer.1. Introduction
Nowadays, new incidence of gastric cancer is more than 1
million each year all over the world and China accounts for more
than 40%. The death toll caused by gastric cancer is about eight
hundred thousand each year all over the world and China ac-
counts for 35%. Its morbidity and mortality account for larger
proportion around the world. At present, a quarter death causes
of domestic people are gastric cancer and the causes of cancer
death are about a quarter of gastric cancer. Surgical resection and
intravenous chemotherapy are the mainly methods to treat
gastric cancer in clinic. Cisplatin is a commonly usedchemotherapy drug and intravenous administration is the most
commonly used method by using cisplatin to conduct chemo-
therapy in clinic. Although cisplatin can exert a certain lethal
effect on cancer cells, it has a lower concentration and relatively
limited lethal effect as well as can cause many adverse reactions
and whole poor tolerance and compliance of patients. In addi-
tion, intravenous administration cannot continuously exert the
lethal effect on cancer cells in tumor tissues [1,2]. A new type of
cisplatin implants is an agent with long-acting anti-tumor effect
and can release cisplatin continuously and exert persistent
antitumor effect [3]. Nowadays, the research on cisplatin
implants used to treat gastric cancer is deﬁcient and its
speciﬁc effect on killing cancer cells and molecular
mechanism are not entirely clear. In the following study, we
built an animal model of tumor-bearing mice with gastric can-
cer and analyzed the growth condition of transplantation tumor
and the inﬂuence of KLK-7 expression and E-cad expression by
administrating cisplatin implants.rticle under the CC BY-NC-ND license (http://
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2.1. Experimental materials
A total of 60 male BALB/c nude mice were selected as
experimental animals, which were purchased from Laboratory
Animal Center, Hainan Medical College and this research was
approved by Ethics Committee of Afﬁliated Hospital of Hainan
Medical College. Cell strain SGC7901 was purchased from
Shanghai Cell Bank of Chinese Academy Sciences. Cisplatin
slow-release implants was purchased from Anhui BBCA Phar-
maceutical Co., Ltd. and cisplatin injection was purchased from
Shanghai Xudong Haipu Pharmaceutical Co., Ltd. RPMI1640
medium and fetal calf serum were purchased from Hyclone Co.,
Ltd. Enzyme linked immunoabsorbent kit was purchased from
Wuhan Boster Biological Engineering Co., Ltd.
2.2. Experimental methods
2.2.1. Dividing methods
Nude mice collected were randomly divided into model
control group (Group A), tail intravenous injection of cisplatin
group (Group B), intratumor injection of cisplatin group (Group
C) and cisplatin implants treatment group (Group D) with 15
mice in each group. A tumor-burdened mouse model with
gastric cancer was established in nude mice of four groups ac-
cording to the following methods: culture cell strains SGC7901
were collected in logarithmic growth phase after ampliﬁcation
from generation to generation and adjusted the density of cells
into 1.5 × 108/mL, and 0.2 mL cell suspension was injected into
axilla of right anterior limb and the tumor was formed with
diameter over 5 cm after 10 days. Mice in A–D Group were
intervened according to the following methods: Group A was
given PBS intratumor injection and caudal vein injection and the
dose was referenced to Group B and Group C; Group B was
given 1 mg/kg cisplatin injection by intratumor injection; Group
C was given 1 mg/kg cisplatin injection by caudal vein injection
and Group D was given 0.4 mg/kg cisplatin implants, which
were placed in enterocoelia.
2.2.2. Animal specimen collection methods
On Day 20, Day 30, Day 40 after treatment, 5 mice were
selected from each group and were sacriﬁced using cervical
dislocation method. The blood was pumped through heart, and
serum was obtained and preserved at −80 C after centrifuga-
tion. Transplanted tumor tissue was dissected and tumor weight
of each week was weighted. The longest diameter and the
shortest diameter of tumor were measured by using micrometer.
The volume of tumor tissue was calculated by the following
formula: V = 0.5 × the longest diameter × the shortest diameter2.Table 1
Comparison of transplanted tumor weight and volume of tumor-bearing mic
Groups Transplantation tumor weight (mg)
Day 20 Day 30 Day 40
Group A 1.52 ± 0.22 1.96 ± 0.25 2.77 ± 0.41
Group B 1.04 ± 0.14a 0.88 ± 0.10a 0.73 ± 0.09
Group C 0.79 ± 0.08ab 0.66 ± 0.07ab 0.61 ± 0.08
Group D 0.33 ± 0.06abc 0.28 ± 0.04abc 0.22 ± 0.04
aP < 0.05, compared with Group A; bP < 0.05, compared with Group B; cAfter that, tumor tissue was quickly frozen in liquid nitrogen and
preserved at −80 C ﬁnally.
2.2.3. Detection methods of animal specimen
Serum specimen was collected and the contents of KLK-7
and E-cad were measured using enzyme-linked immunosor-
bent determination kit. Tumor tissue was collected and ho-
mogenized after adding PBS. After homogenizing, the
suspension was centrifuged and discarded sediment, and then
the supernatant was reserved. The contents of KLK-7 and E-cad
were measured using enzyme-linked immunosorbent determi-
nation kit.
2.3. Statistical methods
Data were inputted using SPSS20.0 software and were sta-
tistically processed. ANOVA was used to compare the mea-
surement data among four groups and pairwise comparison was
conducted using LSD-t test. Differences were statistically sig-
niﬁcant at P < 0.05.
3. Results
3.1. Weight and volume of tumor tissue
On Day 20, Day 30 and Day 40 after treatment, the weight
and volume of transplantation tumors of tumor-bearing mice in
four groups were different (Group A > Group B > Group
C > Group D). The concrete analysis was as follows: trans-
planted tumor weight and volume of tumor-bearing mice in
Group B, Group C and Group D were all lower than those in
Group A. Transplanted tumor weight and volume of tumor-
bearing mice in Group C and Group D were all lower than
those in Group B and transplanted tumor weight and volume of
tumor-bearing mice in Group D were all lower than those in
Group C (Table 1).
3.2. KLK-7 content in tumor tissue and serum
On Day 20, Day 30 and Day 40 after treatment, KLK-7
content in tumor tissue and serum of tumor-bearing mice in
four groups were different (Group A > Group B > Group
C > Group D). The concrete analysis was as follows: KLK-7
content in tumor tissue and serum of tumor-bearing mice in
Group B, Group C and Group D were all lower than those in
Group A; KLK-7 content in tumor tissue and serum of tumor-
bearing mice in Group C and Group D were all lower than
those in Group B and KLK-7 content in tumor tissue and serum
of tumor-bearing mice in Group D were all lower than those in
Group C (Table 2).e in four groups on Day 20, Day 30 and Day 40.
Transplantation tumor volume (cm3)
Day 20 Day 30 Day 40
1.47 ± 0.19 2.18 ± 0.28 2.85 ± 0.42
a 1.15 ± 0.14a 1.02 ± 0.13a 0.87 ± 0.11a
ab 0.88 ± 0.10ab 0.69 ± 0.08ab 0.56 ± 0.07ab
abc 0.48 ± 0.07abc 0.33 ± 0.05abc 0.24 ± 0.05abc
P < 0.05, compared with Group C.
Table 2
Comparison of KLK-7 content in tumor tissue and serum of tumor-bearing mice in four groups on Day 20, Day 30 and Day 40.
Groups KLK-7 content in serum (pg/mL) KLK-7 content in tumor tissue (pg/mg total protein)
Day 20 Day 30 Day 40 Day 20 Day 30 Day 40
Group A 234.61 ± 41.32 331.44 ± 54.52 508.42 ± 62.75 68.75 ± 9.51 103.35 ± 15.75 147.66 ± 20.39
Group B 176.65 ± 31.47a 143.26 ± 28.69a 117.63 ± 20.47a 50.27 ± 8.16a 39.68 ± 7.45a 33.46 ± 6.37a
Group C 136.78 ± 22.16ab 119.57 ± 23.64ab 93.65 ± 12.62ab 41.54 ± 6.74ab 29.35 ± 5.14ab 21.36 ± 4.89ab
Group D 93.74 ± 10.39abc 70.66 ± 9.41abc 56.75 ± 8.75abc 23.31 ± 4.79abc 17.84 ± 2.85abc 11.36 ± 2.03abc
aP < 0.05, compared with Group A; bP < 0.05, compared with Group B; cP < 0.05, compared with Group C.
Table 3
Comparison of E-cad content in tumor tissue and serum of tumor-bearing mice in four groups on Day 20, Day 30 and Day 40.
Groups E-cad content in serum (ng/mL) E-cad content in tumor tissue (ng/mg total protein)
Day 20 Day 30 Day 40 Day 20 Day 30 Day 40
Group A 42.32 ± 6.89 30.48 ± 6.39 22.15 ± 3.68 13.42 ± 1.87 10.14 ± 1.62 7.93 ± 0.92
Group B 53.42 ± 6.92a 67.65 ± 8.14a 82.45 ± 10.25a 18.33 ± 2.74a 25.52 ± 4.26a 31.68 ± 5.15a
Group C 65.16 ± 9.38ab 83.53 ± 10.63ab 104.62 ± 13.36ab 23.51 ± 4.16ab 30.24 ± 5.21ab 36.43 ± 5.57ab
Group D 79.12 ± 10.25abc 107.66 ± 14.68abc 134.68 ± 18.75abc 28.27 ± 4.26abc 41.65 ± 5.17abc 55.72 ± 8.69abc
aP < 0.05, compared with Group A; bP < 0.05, compared with Group B; cP < 0.05, compared with Group C.
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On Day 20, Day 30 and Day 40 after treatment, E-cad con-
tent in tumor tissue and serum of tumor-bearing mice in four
groups were different (Group A < Group B < Group C < Group
D). The concrete analysis was as follows: E-cad content in tumor
tissue and serum of tumor-bearing mice in Group B, Group C
and Group D were all higher than those in Group A; E-cad
content in tumor tissue and serum of tumor-bearing mice in
Group C and Group D were all higher than those in Group B and
E-cad content in tumor tissue and serum of tumor-bearing mice
in Group D were all higher than those in Group C (Table 3).
4. Discussion
Cisplatin is the commonly chemotherapy drug used in gastric
cancer, which can effectively kill gastric cancer cells, induce
tumor cell apoptosis and inhibit tumor growth. Intravenous
administration is the most commonly approach of chemotherapy
administration, which though can effectively kill gastric cancer
cells, the drug concentration within the tumor lesion is lower and
lethal effect is effective. In addition, chemotherapy drug can
induce viscera function damage effecting on each organ of the
whole body through vein, and lead to a variety of adverse re-
actions and limit the dose of chemotherapy drugs and inﬂuence
the effect of chemotherapy [4–6]. Chemotherapy drug injection
within tumor tissue can form a higher drug concentration in
local and has a stronger killing effect on cancer cells.
However, the degree of difﬁculty of operation for this method
of administration is bigger and is difﬁcult to constant repeated
administration of drugs, therefore it is not suitable for clinic
treatment [7]. Cisplatin implants is a kind of cisplatin slow-
release preparation, which is developed in recent years, and
can release cisplatin slowly and continuously and exert a lethal
effect on cancer cells [8,9].
In this research, we built an animal model of tumor-bearing
mice with gastric cancer and analyzed the effect of tail intra-
venous injection of cisplatin, intratumor injection of cisplatin
and cisplatin implants treatment. Firstly, we evaluate the growthcondition of transplantation tumor by measuring the weight and
volume of tumor tissue and the results showed that the weight
and volume of transplantation tumors of tumor-bearing mice in
four groups were different (Group A > Group B > Group
C > Group D). Thus, our analysis is as follows: (1) transplanted
tumor weight and volume of tumor-bearing mice in Group B,
Group C and Group D were all lower than those in Group A and
intravenous injection of cisplatin, intratumor injection and
cisplatin implants can all inhibit the gastric cancer transplanted
tumor growth; (2) transplanted tumor weight and volume of
tumor-bearing mice in Group C and Group D were all lower than
those in Group B and transplanted tumor weight and volume of
tumor-bearing mice in Group D were all lower than those in
Group C, which reveal that among the three methods of
administration, cisplatin implants have a statistically signiﬁcant
tumor suppression effect, followed by intratumor injection of
cisplatin and intravenous injection of cisplatin has the worst
tumor suppression effect.
KLK family is a molecule family to regulate the cells growth,
adhesion and proliferation, including KLK1-KLK15 (a total of
15 members), among which abnormal expression of KLK-7 is
associated with the occurrence and development of digestive
tract malignancies. Some clinical researches have veriﬁed that
the level of KLK-7 expression in colon cancer tissue has
increased signiﬁcantly and is closely related with proliferation of
cancer cells [10,11]. The research on cells level has showed that
silencing of targeting KLK-7 by siRNA in gastric cancer cells
after the reaction of KLK-7, the cell cycle and cell proliferation
were signiﬁcantly suppressed [12]. We analyzed the KLK-7
content in transplanted tumor tissue and serum sample after
cisplatin treatment and conﬁrmed that different cisplatin prepa-
ration and route of administration are all can inhibit the KLK-7
expression, and reduce KLK-7 content in transplanted tumor
tissue and serum. Moreover, cisplatin implants have a statisti-
cally signiﬁcant effect on inhibiting KLK-7 expression, followed
by intratumor injection of cisplatin and intravenous injection of
cisplatin has the weakest effect on inhibiting KLK-7 expression.
E-cad is a labeled molecule of epithelial cell, which has the
function to regulate the adhesion between cells and cells, and
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of morphological structure of epithelial tissue and its deﬁcient
expression will cause diastasis and reattachment of cancer cells
and further induce local inﬁltration and distant transfer [13,14].
Besides, In the process of occurrence and development of
gastric cancer, epithelial–mesenchymal transition is a
signiﬁcant pathological feature and epithelial cell will lose
polarity and acquire interstitial cell phenotype. The expression
level of epithelial cell markers (E-cad) is reduced signiﬁcantly
and further promote invasion of cancer cells [15]. Several
studies have reported that the expression level of E-cad in
gastric cancer tissue is reduced signiﬁcantly and the process of
EMT is enhanced [16,17]. We analyzed the E-cad content in
transplanted tumor tissue and serum sample after cisplatin
treatment and conﬁrmed that different cisplatin preparation and
route of administration are all can promote the E-cad
expression, and increase E-cad content in transplanted tumor
tissue and serum. Moreover, cisplatin implants have a
statistically signiﬁcant effect on promoting E-cad expression,
followed by intratumor injection of cisplatin and intravenous
injection of cisplatin has the weakest effect on promoting
KLK-7 expression.
In conclusion, cisplatin implants can inhibit the growth of
transplanted tumor tissue and down-regulated KLK7 expression
and up-regulated E-cad expression of tumor-bearing mice with
gastric cancer.
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